Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02509702
Other study ID # Connected2Care
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date August 17, 2015
Est. completion date October 6, 2019

Study information

Verified date December 2021
Source Odense University Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study evaluates the effect of the SMS intervention 'Connected2Care' on the attendance rate to cervical cancer screening follow-up appointments.


Description:

Connected2Care is a non-blinded, multicentre, parallel-group, randomised controlled trial. Tanzanian Women testing positive to HR HPV at inclusion are randomly assigned in an allocation ratio of 1:1 to the SMS intervention or the control group (standard care). In a period of 10 months, the intervention group will receive 15 one-directional health educative text messages and SMS-reminders for their appointment. The total sample size will be 700 with 350 women in each study arm. Primary outcome is attendance rate for follow-up. Secondary objectives are cost-effectiveness measured through incremental ratios and knowledge of cervical cancer by a 16-item true/false scale questionnaire at baseline and follow-up.


Recruitment information / eligibility

Status Completed
Enrollment 705
Est. completion date October 6, 2019
Est. primary completion date October 6, 2019
Accepts healthy volunteers No
Gender Female
Age group 25 Years to 60 Years
Eligibility Inclusion Criteria: - Informed consent - HPV positive - Age 25 - 60 years - Private mobile phone Exclusion Criteria: - Pregnant on day of enrolment - Menstruating on day of enrolment - Hysterectomy - Diagnosed with cervical pre-cancer within past 12 months - Diagnosed with cervical cancer - Invalid mobile phone number - Unreachable when trying to convey HPV positive result

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Connected to Care
10 health educative SMSs' sent once a month 5 SMS-reminders for follow-up appointment sent on days -14, -7, -1 pre- follow-up appointment, and +1, +7 post follow-up appointment

Locations

Country Name City State
Tanzania Ocean Road Cancer Institute (ORCI) Dar es Salaam
Tanzania Kilimanjaro Christian Medical Centre (KCMC) Moshi
Tanzania Mawenzi Regional Referral Hospital Moshi Kilimanjaro

Sponsors (1)

Lead Sponsor Collaborator
Marianne Andersen

Country where clinical trial is conducted

Tanzania, 

References & Publications (1)

Linde DS, Andersen MS, Mwaiselage JD, Manongi R, Kjaer SK, Rasch V. Text messages to increase attendance to follow-up cervical cancer screening appointments among HPV-positive Tanzanian women (Connected2Care): study protocol for a randomised controlled trial. Trials. 2017 Nov 21;18(1):555. doi: 10.1186/s13063-017-2215-x. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other Cost-effectiveness of intervention Incremental cost-effectiveness ratio Baseline + 14 months
Other Knowledge of cervical cancer and screening 16 item true-false questionaire Baselie + 14 months
Primary Effect of SMS intervention on attendance rate to follow-up screening appointment The effect measure of the intervention is the 14-month follow-up attendance rate for HPV positive women. The number of women in the intervention group that attend follow-up screening will be compared to the the number of women that attend follow-up screening in the control group. up to 14 months
Secondary Acceptability of text message intervention 6-point Likert scale (1: I do not like it at all - 6: I like it very much) Baseline + 2 years Follow-up (likert scale)
Secondary Acceptability of text message intervention Qualitative interviews. Open-ended 2 years
See also
  Status Clinical Trial Phase
Recruiting NCT06223308 - A Study Evaluating the Safety and Efficacy of HB0028 in Subjects With Advanced Solid Tumors Phase 1/Phase 2
Terminated NCT03367871 - Combination Pembrolizumab, Chemotherapy and Bevacizumab in Patients With Cervical Cancer Phase 2
Active, not recruiting NCT04537156 - Efficacy, Immunogenicity and Safty Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli) Phase 3
Recruiting NCT03668639 - Safety and Antiemetic Efficacy of Akynzeo Plus Dexamethasone During Radiotherapy and Concomitant Weekly Cisplatin Phase 2/Phase 3
Active, not recruiting NCT04242199 - Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors Phase 1
Withdrawn NCT04806945 - A Phase III Study to Evaluate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy in Patients With Advanced Cervical Cancer Phase 3
Active, not recruiting NCT04185389 - Long-Term Follow-Up of HPV FOCAL Participants
Withdrawn NCT03007771 - Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia Phase 1
Completed NCT03384511 - The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies. Phase 4
Recruiting NCT05107674 - A Study of NX-1607 in Adults With Advanced Malignancies Phase 1
Completed NCT05120167 - Strategies for Endocervical Canal Investigation in Women With Abnormal Screening Cytology and Negative Colposcopy N/A
Recruiting NCT05483491 - KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer Phase 1
Recruiting NCT05736588 - Elimisha HPV (Human Papillomavirus) N/A
Completed NCT05862844 - Promise Women Project N/A
Recruiting NCT04934982 - Laparoscopic or Abdominal Radical Hysterectomy for Cervical Cancer(Stage IA1 With LVSI, IA2) N/A
Recruiting NCT03876860 - An Enhanced Vaginal Dilator to Reduce Radiation-Induced Vaginal Stenosis N/A
Completed NCT03652077 - A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies Phase 1
Completed NCT00543543 - Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001) Phase 3
Terminated NCT04864782 - QL1604 Plus Chemotherapy in Subjects With Stage IVB, Recurrent, or Metastatic Cervical Cancer Phase 2/Phase 3
Recruiting NCT04226313 - Self-sampling for Non-attenders to Cervical Cancer Screening N/A